This study is in progress, not accepting new patients

A 5-year Longitudinal Observational Study of Patients Undergoing Therapy for Inflammatory Bowel Disease

a study on Inflammatory Bowel Disease Crohn's Disease Ulcerative Colitis Indeterminate Colitis

Summary

Eligibility
for people ages 2 years and up (full criteria)
Location
at UC Davis
Dates
study started
study ends around

Description

Summary

TARGET-IBD is a 5-year, longitudinal, observational study of adult and pediatric patients (age 2 and above) being managed for Inflammatory Bowel Disease (IBD) in usual clinical practice. TARGET-IBD will create a research registry of patients with IBD within academic and community real-world practices in order to assess the safety and effectiveness of current and future therapies.

Keywords

Inflammatory Bowel Diseases, Crohn's Disease, Ulcerative Colitis, Indeterminate Colitis, Digestive System Diseases, Crohn Disease

Eligibility

You can join if…

Open to people ages 2 years and up

  1. Adults and children (age 2 or older) with a diagnosis of Crohn's disease (CD), Ulcerative colitis (UC), or Indeterminate colitis (IBDU) having been prescribed any IBD treatment (initial or subsequent) outside of a clinical trial.
  2. Have plans for future visits at the site for continued management of IBD.

You CAN'T join if...

  1. Inability to provide written informed consent/assent.
  2. Being enrolled in any interventional study or trial for IBD treatment. Note: Patient may be enrolled in other registries or studies where IBD treatment outcomes are observed and/or reported (such as center-based registries).
  3. Prior total abdominal colectomy for UC or IBDU.

Locations

  • University of California - Davis
    Sacramento California 95817 United States
  • FACEY Medical Foundation
    Mission Hills California 91345 United States
  • Stanford University
    Stanford California 94305 United States

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Target PharmaSolutions, Inc.
ID
NCT03251118
Study Type
Observational [Patient Registry]
Participants
Expecting 15000 study participants
Last Updated